Dr Craig dick
- Honorary Clinical Senior Lecturer (School of Medicine, Dentistry & Nursing)
email:
Craig.Dick@glasgow.ac.uk
Dept of Pathology, QEUH, 1345 Govan Roadq, G51 OSF
Publications
2024
Frankell, A. M. et al. (2024) Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature, 631(8022), E15. (doi: 10.1038/s41586-024-07738-w) (PMID:38965439)
2023
Abbosh, C. et al. (2023) Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature, 616(7957), pp. 553-562. (doi: 10.1038/s41586-023-05776-4) (PMID:37055640)
Al Bakir, M. et al. (2023) The evolution of non-small cell lung cancer metastases in TRACERx. Nature, 616, pp. 534-542. (doi: 10.1038/s41586-023-05729-x) (PMID:37046095) (PMCID:PMC10115651)
Frankell, A. M. et al. (2023) The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature, 616, pp. 525-533. (doi: 10.1038/s41586-023-05783-5) (PMID:37046096) (PMCID:PMC10115649)
Martínez-Ruiz, C. et al. (2023) Genomic–transcriptomic evolution in lung cancer and metastasis. Nature, 616, pp. 543-552. (doi: 10.1038/s41586-023-05706-4) (PMID:37046093) (PMCID:PMC10115639)
Ng, K. W. et al. (2023) Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature, 616, pp. 563-573. (doi: 10.1038/s41586-023-05771-9) (PMID:37046094) (PMCID:PMC10115647)
Hill, W. et al. (2023) Lung adenocarcinoma promotion by air pollutants. Nature, 616(7955), pp. 159-167. (doi: 10.1038/s41586-023-05874-3) (PMID:37020004)
Al-Sawaf, O. et al. (2023) Body composition and lung cancer-associated cachexia in TRACERx. Nature Medicine, 29(4), pp. 846-858. (doi: 10.1038/s41591-023-02232-8) (PMID:37045997) (PMCID:PMC7614477)
Karasaki, T. et al. (2023) Evolutionary characterization of lung adenocarcinoma morphology in TRACERx. Nature Medicine, 29(4), pp. 833-845. (doi: 10.1038/s41591-023-02230-w) (PMID:37045996) (PMCID:PMC7614478)
2020
AbdulJabbar, K. et al. (2020) Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nature Medicine, 26(7), pp. 1054-1062. (doi: 10.1038/s41591-020-0900-x) (PMID:32461698)
Jackson, M. R. , Ashton, M., Koessinger, A. L., Dick, C., Verheij, M. and Chalmers, A. J. (2020) Mesothelioma cells depend on the anti-apoptotic protein Bcl-xL for survival and are sensitized to ionizing radiation by BH3-mimetics. International Journal of Radiation Oncology, Biology, Physics, 106(4), pp. 867-877. (doi: 10.1016/j.ijrobp.2019.11.029) (PMID:31786278)
2019
Neidler, S. et al. (2019) Identification of a clinically relevant signature for early progression in KRAS-driven lung adenocarcinoma. Cancers, 11(5), 600. (doi: 10.3390/cancers11050600) (PMID:31032816) (PMCID:PMC6562816)
2018
Lindsay, C. R. et al. (2018) Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. ESMO Open, 3(6), e000408. (doi: 10.1136/esmoopen-2018-000408) (PMID:30233821) (PMCID:PMC6135448)
Tsim, S. et al. (2018) Early Contrast Enhancement: a novel Magnetic Resonance Imaging biomarker of pleural malignancy. Lung Cancer, 118, pp. 48-56. (doi: 10.1016/j.lungcan.2018.01.014) (PMID:29572002) (PMCID:PMC5884311)
Articles
Frankell, A. M. et al. (2024) Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature, 631(8022), E15. (doi: 10.1038/s41586-024-07738-w) (PMID:38965439)
Abbosh, C. et al. (2023) Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature, 616(7957), pp. 553-562. (doi: 10.1038/s41586-023-05776-4) (PMID:37055640)
Al Bakir, M. et al. (2023) The evolution of non-small cell lung cancer metastases in TRACERx. Nature, 616, pp. 534-542. (doi: 10.1038/s41586-023-05729-x) (PMID:37046095) (PMCID:PMC10115651)
Frankell, A. M. et al. (2023) The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature, 616, pp. 525-533. (doi: 10.1038/s41586-023-05783-5) (PMID:37046096) (PMCID:PMC10115649)
Martínez-Ruiz, C. et al. (2023) Genomic–transcriptomic evolution in lung cancer and metastasis. Nature, 616, pp. 543-552. (doi: 10.1038/s41586-023-05706-4) (PMID:37046093) (PMCID:PMC10115639)
Ng, K. W. et al. (2023) Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature, 616, pp. 563-573. (doi: 10.1038/s41586-023-05771-9) (PMID:37046094) (PMCID:PMC10115647)
Hill, W. et al. (2023) Lung adenocarcinoma promotion by air pollutants. Nature, 616(7955), pp. 159-167. (doi: 10.1038/s41586-023-05874-3) (PMID:37020004)
Al-Sawaf, O. et al. (2023) Body composition and lung cancer-associated cachexia in TRACERx. Nature Medicine, 29(4), pp. 846-858. (doi: 10.1038/s41591-023-02232-8) (PMID:37045997) (PMCID:PMC7614477)
Karasaki, T. et al. (2023) Evolutionary characterization of lung adenocarcinoma morphology in TRACERx. Nature Medicine, 29(4), pp. 833-845. (doi: 10.1038/s41591-023-02230-w) (PMID:37045996) (PMCID:PMC7614478)
AbdulJabbar, K. et al. (2020) Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nature Medicine, 26(7), pp. 1054-1062. (doi: 10.1038/s41591-020-0900-x) (PMID:32461698)
Jackson, M. R. , Ashton, M., Koessinger, A. L., Dick, C., Verheij, M. and Chalmers, A. J. (2020) Mesothelioma cells depend on the anti-apoptotic protein Bcl-xL for survival and are sensitized to ionizing radiation by BH3-mimetics. International Journal of Radiation Oncology, Biology, Physics, 106(4), pp. 867-877. (doi: 10.1016/j.ijrobp.2019.11.029) (PMID:31786278)
Neidler, S. et al. (2019) Identification of a clinically relevant signature for early progression in KRAS-driven lung adenocarcinoma. Cancers, 11(5), 600. (doi: 10.3390/cancers11050600) (PMID:31032816) (PMCID:PMC6562816)
Lindsay, C. R. et al. (2018) Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. ESMO Open, 3(6), e000408. (doi: 10.1136/esmoopen-2018-000408) (PMID:30233821) (PMCID:PMC6135448)
Tsim, S. et al. (2018) Early Contrast Enhancement: a novel Magnetic Resonance Imaging biomarker of pleural malignancy. Lung Cancer, 118, pp. 48-56. (doi: 10.1016/j.lungcan.2018.01.014) (PMID:29572002) (PMCID:PMC5884311)